Royalty Pharma (MEX:RPRXN) Minority Interest: MXN51,526.46 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RPRXN Royalty Pharma PLC MEX:RPRXN
65 GF Score
Price MXN1,025.44
GF Value MXN559.33
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Minority Interest?

Royalty Pharma MEX:RPRXN 65 Minority Interest is MXN51,526.46 Mil as of Jun. 2026. GuruFocus rates MEX:RPRXN with a GF Score™ of 65/100 and a GF Value™ of MXN559.33 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Royalty Pharma's minority interest for the quarter that ended in Jun. 2026 was MXN51,526.46 Mil.

Royalty Pharma Minority Interest Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Minority Interest Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only 91,737.60 75,980.26 60,390.84 70,821.47 58,303.16

Royalty Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59,406.69 58,820.92 58,303.16 54,968.85 51,526.46
MEX:RPRXN
65GF Score
Royalty Pharma PLC MEX:RPRXN
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of MXN51,526.46 Mil mean?
Royalty Pharma (MEX:RPRXN) has a Minority Interest of MXN51,526.46 Mil as of Jun. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Royalty Pharma.
Is Royalty Pharma's Minority Interest too high?
Royalty Pharma's current Minority Interest is MXN51,526.46 Mil. Overall, Royalty Pharma has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Minority Interest compare to ROIV and INCY?
Royalty Pharma's Minority Interest of MXN51,526.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Royalty Pharma. Royalty Pharma's current Minority Interest is MXN51,526.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (MEX:RPRXN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN559.33, compared to a current price of MXN1,025.44 — trading 83.3% above its estimated fair value. The current Minority Interest is MXN51,526.46 Mil. Royalty Pharma's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Minority Interest is MXN51,526.46 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of MXN1,025.44 is trading 83.3% above its estimated GF Value™ of MXN559.33. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for MEX:RPRXN:

  • Minority Interest: MXN51,526.46 Mil
  • GF Value™: MXN559.33 vs. price of MXN1,025.44 (83.3% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
65GF Score

Get the complete analysis for MEX:RPRXN

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,025.44
Price
MXN559.33
GF Value